Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-12-12
1997-08-19
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
540580, 544349, 544357, 546 17, 546112, 546187, 548465, A61K 31445, C07D51900, C07D40106, C07D40112
Patent
active
056589212
ABSTRACT:
The subject invention describes Novel dimer 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having the general Formula I: ##STR1## wherein n is 1-5;
REFERENCES:
patent: 2891066 (1959-06-01), Parcell
patent: 3408356 (1968-10-01), Horovitz
patent: 3476760 (1969-11-01), Kaiser et al.
patent: 3558637 (1971-01-01), Kaiser et al.
patent: 3686186 (1972-08-01), Houlihan et al.
patent: 3745165 (1973-07-01), Houlihan et al.
patent: 3962259 (1976-06-01), Bauer et al.
patent: 3980658 (1976-09-01), Possanza et al.
patent: 3985889 (1976-10-01), Bauer et al.
patent: 3996211 (1976-12-01), Lassen
patent: 4038395 (1977-07-01), Lassen
patent: 4208417 (1980-06-01), Uzan et al.
patent: 4420485 (1983-12-01), Davis et al.
patent: 4443448 (1984-04-01), B.o slashed.ges.o slashed.424250
Gerwitz, Neuropsychopharmacology 10, 37 (1994).
Hudkins, Life. Sci. 49, 1229 (1991).
Bally et al. (1887) Chem. Ber., vol. 20, p. 2590.
Barry et al. (1987), "Withdrawal Syndrome Following Subchronic Treatment with Anxiolytic Agents", Pharmac. Biochem. Behav., vol. 27, pp. 239-245.
B.o slashed.ges.o slashed., K. P. et al. (1985), "3-Phenyl-1-indanamines. Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake", J. Med. Chem., vol. 28, pp. 1817-1828.
B.o slashed.ges.o slashed., K. P. (1983), "Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans", J. Med. Chem., vol. 26, pp. 935-947.
Hyttel, J. et al. (1985), "Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin", J. Neurochem., vol. 44, pp. 1615-1622.
Allen, R. C. et al. (1978), "Synthesis of Spiro[isobenzofuran-1(3H), 4'-piperidines] as Potential Central Nervous System Agents. 4. Central Nervous System Depressants", J. Med. Chem., vol. 21, No. 11, pp. 1149-1154.
Perregaard et al. (1992), "Noncataleptogenic, Centrally Acting Dopamine D-2 and Serotonin 5-HT.sub.2 Antagonists within a Series of 3-Substituted 1-(4-Flurophenyl)-1H-Indoles", J. Med. Chem., vol. 35, pp. 1092-1101.
Martin et al. (1989), "Affinity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy", J. Med. Chem., vol. 32, pp. 1052-1056.
Marxer et al. (1975), "Spiro Piperidines. I. Synthesis of Spiro[isobenzofuran-1(3H), 4'-Piperidines] and Spiro[isobenzofuran-1(3H,3'-piperidines]", J. Org. Chem., vol. 40, No. 10, pp. 1427-1433.
McElvain, S. M. et al. (1950), "Piperidine Derivatives. XXIII. Certain Halogenated 1-Methyl-4-Phenylpiperidines and Related Compounds", J. Amer. Chem. Soc., vol. 72, pp. 3134-3138.
McMillen, B. A. et al. (1988), "N-Alkyl-Substituted Aryl-Piperazine Drugs: Relationship Between Affinity for Serotonin Receptors and Inhibition of Aggression", Drug Develop. Res., vol. 12, pp. 53-62.
Rao, T. S. et al. (1990), "Inhibition of Climbing and Mossy Fiber, and Basket and Stellate Cell Inputs to Mouse Cerebellar Purkinje Cells by Novel Anti-Ischemic Agents, Ifenprodil and BMY-14802", Life Sciences, vol. 47, pp. PL-1-PL-5.
Sanchez et al. (1991), "Neurochemical and In Vivo Pharmacological Profile of Sertindole, a Limbic-Selective Neuroleptic Compound", Drug Deve. Res., vol. 22, pp. 239-250.
Schweizer, E. et al. (1986), "Failure of Buspirone to Manage Benzodiazepine Withdrawal", Am. J. Psychiat., vol. 143, No. 12, pp. 1590-1592.
Skarsfeldt, T. et al. (1990), "Sertindole, A New Neuroleptic with Extreme Selectivity on A10 Versus A9 Dopamine Neurones in the Rat", Eur. J. Pharmacol., vol. 182, pp. 613-614.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Spiro[isochromanpiperidine] Analogs for Inhibition of Histamine Release", Chem. Pharm. Bull., vol. 29, No. 12, pp. 3494-3498.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Spiro[isochromanpiperidine] Analogues for Inhibition of Histamine Release", J. Med. Chem., vol. 24, pp. 194-198.
Chambers, M. S. et al. (1992), "Spiropiperidines as High-Affinity, Selective .alpha. Ligands", J. Med. Chem., vol. 35, pp. 2033-2039.
Rao, Tadimeti S. et al. (1990), "BMY-14802 Antagonizes Harmaline- and D-Serine-Induced Increases in Mouse Cerebellar Cyclic GMP: Neuorochemical Evidence for a .sigma. Receptor-Mediated Functional Modulation of Responses Mediated by the N-Methyl-D-aspartate Receptor Complex In Vivo", Molecular Pharmacology, vol. 37, pp. 978-982.
Walker, J.M. et al. (1990) Pharmacological Reviews, vol. 42, pp. 355-402.
Earley et al. (1991) Brain Research, vol. 546, pp. 281-286.
Hyttel, J. (1987), "Age Related Decrease in the Density of Dopamine D.sub.1 and D.sub.2 Receptors in Corpus Striatum of Rats", Pharmacology and Toxicology, vol. 61, pp. 126-129.
Hyttel, J. et al. (1988), "Neurochemical Profile In Vitro of Irindalone: A 5-HT.sub.2 -Receptor Antagonist", Drug Dev. Res., vol. 15, pp. 389-404.
Junien et al. (1991), "J01784, A Novel .alpha. Ligand, Potentiates [.sup.3 H]Acetylcholine Release from Rat Hippocampal Slices", Eur. J. Pharm., vol. 200, pp. 343-345.
Matsuno et al. (1992), "Increase of Extracellular Acetylcholine Level in Rat Frontal Cortex Induced by (+)N-allylnormetazocine as Measured by Brain Microdialysis", Brain Research, vol. 545, pp. 315-319.
Parham et al. (1976), J. Org. Chem., vol. 41, pp. 2628-2633.
Skarsfeldt, T. et al. (1986), "The St 587-Induced Flexor Reflex in Pithed Rats: A Model to Evaluate Central .alpha..sub.1 -Receptor Blocking Properties", Eur. J. Pharmacol., vol. 125, pp. 333-340.
Van der Weide, J. et al. (1987), "In Vitro Binding of the Very Potent and Selective D-2 Dopamine Agonist, [.sup.3 H]N-0437 to Calf Caudate Membranes", Eur. J. Pharmacol., vol. 134, pp. 211-219.
Weber, E. et al. (1986), "1,3-Di(2-[5-.sup.3 H]tolyl)guanidine: A Selective Ligand that Labels .alpha.-type Receptors for Psychotomimetic Opiates and Antipsychotic Drugs", Proc. Natl. Acad. Sci., vol. 83, pp. 8784-8788.
Snyder, S.H. et al. (1989), "Receptor Mechanisms in Antipsychotic Drug Action: Focus on Sigma Receptors," Neuropsychiatry, vol. 1, pp. 7-15.
Colpaert, F.C. et al. (1985), Abstract of Psychopharmacology, vol. 86, pp. 45-54.
Moltzen Ejner K.
Perregaard Jens
Stenberg John W.
Berch Mark L.
H. Lundbeck A/S
LandOfFree
Dimeric piperidine, tetrahydropyridine and piperazine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dimeric piperidine, tetrahydropyridine and piperazine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimeric piperidine, tetrahydropyridine and piperazine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1105059